Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). Article

Omuro, Antonio Marcilio Padula, DeAngelis, Lisa Marie, Karrison, Theodore et al. (2020). Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL). . JOURNAL OF CLINICAL ONCOLOGY, 38(15_suppl), 2501-2501. 10.1200/jco.2020.38.15_suppl.2501

cited authors

  • Omuro, Antonio Marcilio Padula; DeAngelis, Lisa Marie; Karrison, Theodore; Bovi, Joe A; Rosenblum, Marc; Corn, Benjamin W; Correa, Denise; Wefel, Jeffrey Scott; Aneja, Sanjay; Grommes, Christian; Schaff, Lauren; Waggoner, Steven E; Lallana, Enrico C; Werner-Wasik, Maria; Iwamoto, Fabio; Robinson, Timothy J; Donnelly, Eric; Struve, Timothy; Won, Minhee; Mehta, Minesh P

authors

publication date

  • May 20, 2020

published in

keywords

  • 32 Biomedical and Clinical Sciences
  • 3201 Cardiovascular Medicine and Haematology
  • 3202 Clinical Sciences
  • 3211 Oncology and Carcinogenesis
  • 6 Evaluation of treatments and therapeutic interventions
  • 6.1 Pharmaceuticals
  • 6.5 Radiotherapy and other non-invasive therapies
  • Cancer
  • Clinical Research
  • Clinical Trials and Supportive Activities
  • Hematology

Digital Object Identifier (DOI)

publisher

  • American Society of Clinical Oncology (ASCO)

start page

  • 2501

end page

  • 2501

volume

  • 38

issue

  • 15_suppl